Drug intelligence / Profile preview

HB-201

Development stage: Phase 2
Lead developer: HOOKIPA Pharma
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intravenous

Overview

HB-201 is a replication-competent, live attenuated cancer immunotherapy based on the arenavirus Lymphocytic Choriomeningitis Virus (LCMV) vector. It encodes a non-oncogenic fusion protein of the E6 and E7 antigens from human papillomavirus type 16 (HPV16). Upon administration, HB-201 induces expression of these viral proteins in host cells, stimulating a robust immune response—particularly cytotoxic T cell responses—targeted against HPV16-positive tumor cells. The drug is being developed primarily for the treatment of HPV-associated cancers, especially head and neck squamous cell carcinoma (HNSCC), but also other HPV16+ cancers. It is part of Hookipa Pharma’s proprietary replicating arenaviral vector platform and can be used as monotherapy or in combination with other agents such as anti-PD1 therapies[1][2][3][4][5][6][8].

Other names: HPV E6/E7-encoding arenavirus vaccine HB-201

Targets

HPV16 E6 oncoprotein

Beyond the preview

Go deeper on HB-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HB-201.

Explore the full profile